231 related articles for article (PubMed ID: 7951392)
1. Scientific hypothesis: a new strategy for the design of anti-protozoal drugs--DNA polymerase as a drug target.
Biñas M; Johnson AM
Appl Parasitol; 1994 Sep; 35(3):157-68. PubMed ID: 7951392
[TBL] [Abstract][Full Text] [Related]
2. [Target points of antiparasitic drugs].
Boczoń K
Wiad Parazytol; 1988; 34(4-6):529-43. PubMed ID: 3071915
[No Abstract] [Full Text] [Related]
3. The cell cycle of parasitic protozoa: potential for chemotherapeutic exploitation.
Hammarton TC; Mottram JC; Doerig C
Prog Cell Cycle Res; 2003; 5():91-101. PubMed ID: 14593704
[TBL] [Abstract][Full Text] [Related]
4. Targeting DHFR in parasitic protozoa.
Anderson AC
Drug Discov Today; 2005 Jan; 10(2):121-8. PubMed ID: 15718161
[TBL] [Abstract][Full Text] [Related]
5. DNA topoisomerases as targets for antiprotozoal therapy.
Bakshi RP; Shapiro TA
Mini Rev Med Chem; 2003 Sep; 3(6):597-608. PubMed ID: 12871162
[TBL] [Abstract][Full Text] [Related]
6. [Type I DNA topoisomerase from protozoan pathogens as a potential target for anti-tumoral drugs].
Reguera RM; Pérez-Pertejo Y; Redondo CM; Díaz-González R; Balaña-Fouce R
Medicina (B Aires); 2007; 67(6 Pt 2):747-57. PubMed ID: 18422072
[TBL] [Abstract][Full Text] [Related]
7. [Drugs for protozoan diseases].
Ohta N
Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():380-3. PubMed ID: 17455649
[No Abstract] [Full Text] [Related]
8. Reporter genes facilitating discovery of drugs targeting protozoan parasites.
Dube A; Gupta R; Singh N
Trends Parasitol; 2009 Sep; 25(9):432-9. PubMed ID: 19720564
[TBL] [Abstract][Full Text] [Related]
9. Polyamine transport in parasites: a potential target for new antiparasitic drug development.
Reguera RM; Tekwani BL; Balaña-Fouce R
Comp Biochem Physiol C Toxicol Pharmacol; 2005 Feb; 140(2):151-64. PubMed ID: 15907761
[TBL] [Abstract][Full Text] [Related]
10. Hypoxanthine-guanine phosphoribosyltransferase as a therapeutic target in protozoal infections.
Ullman B; Carter D
Infect Agents Dis; 1995 Mar; 4(1):29-40. PubMed ID: 7728354
[TBL] [Abstract][Full Text] [Related]
11. New mechanisms of drug resistance in parasitic protozoa.
Borst P; Ouellette M
Annu Rev Microbiol; 1995; 49():427-60. PubMed ID: 8561467
[TBL] [Abstract][Full Text] [Related]
12. Peptide deformylase of eukaryotic protists: a target for new antiparasitic agents?
Meinnel T
Parasitol Today; 2000 Apr; 16(4):165-8. PubMed ID: 10725904
[TBL] [Abstract][Full Text] [Related]
13. The current status of antiparasite chemotherapy.
Croft SL
Parasitology; 1997; 114 Suppl():S3-15. PubMed ID: 9309765
[TBL] [Abstract][Full Text] [Related]
14. Lincomycin, clindamycin and their applications.
Spízek J; Rezanka T
Appl Microbiol Biotechnol; 2004 May; 64(4):455-64. PubMed ID: 14762701
[TBL] [Abstract][Full Text] [Related]
15. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
16. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
17. Nitroheterocyclic drugs with broad spectrum activity.
Raether W; Hänel H
Parasitol Res; 2003 Jun; 90 Supp 1():S19-39. PubMed ID: 12811546
[TBL] [Abstract][Full Text] [Related]
18. Targeting polyamines of parasitic protozoa in chemotherapy.
Müller S; Coombs GH; Walter RD
Trends Parasitol; 2001 May; 17(5):242-9. PubMed ID: 11323309
[TBL] [Abstract][Full Text] [Related]
19. Development of cysteine protease inhibitors as chemotherapy for parasitic diseases: insights on safety, target validation, and mechanism of action.
McKerrow JH
Int J Parasitol; 1999 Jun; 29(6):833-7. PubMed ID: 10480720
[TBL] [Abstract][Full Text] [Related]
20. Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets.
Coombs GH; Goldberg DE; Klemba M; Berry C; Kay J; Mottram JC
Trends Parasitol; 2001 Nov; 17(11):532-7. PubMed ID: 11872398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
